Team:Thessaloniki/Human Practices

☰







Human Practices





Overview


During our research journey, we contacted numerous entities that aided in overcoming every obstacle that appeared in our way and also helped us to understand the importance of our research project. Since pancreatic cancer is one of the most lethal types of cancer, the importance of its early diagnosis is crucial. During our social activities, the selection of the entities that we consulted was based upon eight main categories. This categorization was placed to cover every aspect of diagnostic tool development and distribution from the lab, to manufacturing and the final beneficiaries. Specifically, the pillars that we based upon were the following: industries, doctors, diagnostic centers, associations, the academic community, general public, Entrepreneurship, and Regulatory Entities.






Human Practices





| Academic Community




~Rector & Vice-Rector of Auth

  • During our journey in the iGEM competition, support from our university was crucial. The university provided us with all the research facilities we needed in order to develop our innovative diagnostic tool and also gladly embraced all of our social activities. We presented our project to the Vice-Rector of Aristotle University of Thessaloniki Dr. Eystratio Stylianidi on 04/01/2021 and the Rector of Aristotle University of Thessaloniki Dr. Niko Papaioannou on 05/01/2021, who gladly and warmly wanted to hear more about our research goals and ideas.
  • We aimed to receive their thoughts and feedback about it. They informed us about the high-risk population that would be directly concerned about our idea and also they provided information about planning our future steps for this project to be useful for our society. Besides aiding our team financially, they provided us with valuable advice and congratulated us for the multidisciplinarity and cooperation which our team showed during the development of our idea. On 19/4/2021, the Rector arranged an in-person meeting at his office to meet the whole team and express his warm support for the difficult task we undertook to achieve our goal since our first meeting was online.
~Dr. Kyriakos Kachrimanis, President of School of Pharmacy, AuTh


On the 15th of January our team had an online meeting with Dr. Kyriakos Kachrimanis, President of School of Pharmacy, AuTh. We presented our project and our team’s timeline for our participation in iGEM Competition through this meeting. Firstly, he confirmed that a tool for the early diagnosis will be very helpful to increase the survival rates and to guide the oncologists and doctors for the treatment. To validate the importance of our diagnostic tool, he shared with us the story of a relative of his, who died from pancreatic cancer due to a late diagnosis. So, he emphasized that the production of such a tool should happen as soon as possible, and in this way, he recommended we search for the regulations about a non-invasive molecular diagnostic tool. Finally, he wished us good luck in the competition.
~Dr. Antigoni Malousi and Dr. Xanthopoulos Konstantinos

On the 18th of February we scheduled an online meeting with Dr. Antigoni Malousi, Ph.D., Specialized Teaching Staff, Department of Biochemistry, School of Medicine, AUTH & Dr. Xanthopoulos Konstantinos, Assistant Professor, Department of Pharmacognosy-Pharmacology, School of Pharmacy, AUTH. In this meeting, we discussed modifications in the bioinformatic part of the project which could be done to improve the analysis. More specifically, Dr. Malousi & Dr. Xanthopoulos proposed to focus the whole analysis on one variable, such as the miRNAs that are over or underexpressed in PDAC and that are excreted in urine -but not simultaneously. Thus we will have larger data to analyze and our results would be more certain. Another topic which Dr. Malousi & Dr. Xanthopoulos assisted us with is the databases. They proposed many sites where we could find data appropriate for our analysis. In the end, they listened to the whole idea of our project and said their opinion about it, which was very helpful for the continuation of the project.



| Industries



Another important pillar of our human practices plan of action concerned the companies that could offer their experience and feedback. So we considered that it was very important to understand if our diagnostic tool could be practically materialized for people to be tested. For that reason, we contacted pharmaceutical industries, like Pfizer and Biogenea.



~Pfizer
On the 24th of September, we organized a meeting with Pfizer Hellas, Ms. Karamanou Vasso, the head of the corporate social responsibility team of Pfizer Hellas, and Mr. Aggeloudis Nikolaos, Public Affairs Manager of Pfizer Hellas, to present our project and receive feedback so that we could improve our idea. Apart from their kind support, they pointed out the importance of multidisciplinarity for the development of innovative ideas and they confirmed the importance of early diagnosis of all types of cancer and especially for aggressive ones like PDAC.



~Biogenea

On the 8th of October, we scheduled a meeting with Mr. Nikolaos Grigoriadis, Founder of Biogenea to present our project and receive feedback. According to his research experience, he told us that molecular diagnostic tools will be preferred by doctors and diagnostic centers because they offer accuracy and specificity. Also, he recognized the importance of diagnostic tools for early diagnosis to increase the survival rates and apply effective treatments. In addition, as his company processes urine samples, he recommended helping us with clinical trials in the future. Finally, after the presentation of our progress, the experimental results, and activities he congratulated us and wished us good luck in the competition.



| Associations



~Pharmaceutical Society of Thessaloniki

On the 18th of May, we presented our project METIS via zoom to the president of Pharmaceutical Society, Mr. Eugenidis Dionysios, Pharmacist, and to the vice-president Ms. Sidiropoulou Anna, Pharmacist. Apart from the financial support, they congratulated us for our idea and they recognized the value of our diagnostic tool and the impact on the patients, who suffer from pancreatic cancer. We were told that if it could be done in the form of a rapid test as Self Tests for Covid-19, according to the regulations, they could provide it to the public. So, we explained that our diagnostic method is not that simple and should be executed in microbiological labs of diagnostic centers. Furthermore, we hope our technology will be very affordable so it can be easily accessible to the public. In the last section of our discussion, we described what is the iGEM Competition and what we should do throughout our iGEM journey and they wished us all the best.



~Panhellenic Federation of Associations of People with Diabetes

On the 15th of October we met with Christos Daramilas, President of the Panhellenic Federation of Associations of People with Diabetes (P.F.P.D.) to present our project and to discuss how PDAC affects people with diabetes. We discussed the possibility of comorbidity on these patients as it is probable to encounter both PDAC and Type 2 Diabetes. Also, we talked about the likelihood of diabetes being a clinical sign to PDAC and how this could affect our diagnosis. Furthermore, he noted that our diagnostic method should be prescribed by a doctor to finally reach the patient and not be used in the annual check-up as easily as we thought. Mr. Daramilas also offered to encourage people with diabetes to participate in the clinical trials if our project is advanced to this stage. This will aid in evolving our project, through testing our diagnostic method directly on biological samples. It was a most informative meeting in which he gave us a lot of encouragement and permission for future meetings.



~Society of cancer patients of Macedonia-Thrace

On the 18th of October, we had a meeting with members of the Society of cancer patients of Greece. We had the chance to present our project idea and receive feedback on how it could affect the lives of cancer patients. We received general information on the struggles of patients with PDAC and cancer as a whole. It was a great deal for us to discuss with people who have experienced the stressful cancer diagnosis first hand and could enlighten us with their ideas and suggestions.



| General Public



Through our project, we are not only concerned with its laboratory development but also its approval and usefulness in society.




~85th Thessaloniki International Fair

For this reason, on the 11th of September, we took part in Thessaloniki’s International Fair for its whole duration (11-19/09/2021), to present our project to the public. In this exhibition, we came into contact with a plethora of people to inform them not only about the goals of synthetic biology but also about the importance of our research topic. Since cancer is a scourge of modern society, its early diagnosis is a matter of utter importance and this was validated from the public’s interest. People shared with us their experiences about themselves or their relatives who faced this difficult situation. They also pointed out that early diagnosis is crucial and informed us on how they would most definitely use our diagnostic tool in the future. The fact that the final user of our diagnostic test that we are preparing congratulated us, and gave us so much positive feedback, filled us with courage and eagerness to achieve our goal.

Check out our Photo Album from Thessaloniki International Fair:

TIF Photo Album







~iGEM Meetup: Greek Edition

On the 25th of July, we presented our project in the iGEM MeetUp: Greek edition, a 2-day webinar held by Greek iGEM teams -Thessaloniki, Athens, Crete, NOUS, and Thrace. The Meetup was attended by scientists and students all around the world and even by the Greek iGEM ambassadors. After the presentation, there was a troubleshooting section, where the problems we faced during our project development were analyzed and discussed. During this section, we had the chance to get feedback on our project and even suggestions on how it could be improved. The attendees were particularly interested in the amplification process needed to achieve the necessary sensitivity. Moreover, the Greek Ambassadors suggested emphasizing more on the positive and negative controls we use both in our experiments now and in the future when our project will be a complete product. After this discussion, we searched more on calibrators needed for both METIS kit and device and their proposal changed our future implementation and the way we designed our quantification experiments.

For more information about the iGEM MeetUp: Greek edition visit our Collaborations page:

Collaborations






|Impact Grand



On the 4th of August, we won the Impact Grant from iGEM Headquarters. This validated the value of our project and the impact of our diagnostic technique in order to help to increase the survival rates of Pancreatic Ductal Adenocarcinoma, globally. This Grant supports and motivates our team to continue the experimental procedures in order to prove our concept and try to find a way for easy production of our diagnostic tool in the future. More specifically, it gave us the chance to take a more careful look into the problem of PDAC late diagnosis, which causes high mortality, and into the market that our diagnostic tool will be released in the future.





| Summary



The purpose of our social activities was to validate the importance of our research project for society. We approached entities to cover every aspect of our diagnostic tool development and distribution.
Academic community ~Rector-Vice Rector of AuTh
~Dr. Kyriakos Kachrimanis, President of School of Pharmacy, AuTh
~Dr. Antigoni Malousi and Dr. Xanthopoulos Konstantinos
Industries ~Pfizer
~Biogenea
Associations ~Pharmaceutical Society of Thessaloniki
~Panhellenic Federation of Associations of People with Diabetes
~Society of cancer patients of Macedonia-Thrace
General public ~85th Thessaloniki International Fair
~iGEM Meet up: Greek Edition






Integrated Human Practices




| Academic Community




~Dr. Lefkothea Papadopoulou

On the 14th of June we had an online meeting with Dr. Lefkothea Papadopoulou, Professor of Pharmacology in School of Pharmacy, AuTh to present our project and our timeline for the experimental procedures. According to her lab experience on RNA processing and in vitro protein synthesis she agreed with the use of a Cell-free system to validate the functionality of our Toehold switches. Also, she recommended standardizing the experimental conditions such as the temperature or time of incubation to have repeatable results. Moreover, she highlighted the importance of controls in an experiment to understand if the fluorescence is due to the Toehold switches or is produced by the reagents of the Cell-free system that we utilized. After that, we changed our positive and negative controls and we found out that the background fluorescence of the cell-free system interferes with our measurements.
On the other scale of our discussion, we received a training workshop by Dr. Papadopoulou Lefkothea, to conform to the Basic Lab Biosafety Rules and Regulations, focused on the risks arising from the experiments that we are planning to perform. During this training, we were informed on the waste management protocols of our institution, as well as how to handle hazardous substances we are going to use and how to report an accident to the supervisor of our lab.

For more information visit:

Engineering Success







| Industries




~R.G.C.C. (Research Genetic Cancer Centre)
On 18th of December 2020 we came into contact with Dr. Papasotiriou Ioannis, an oncologist and also founder of the Research Genetic Cancer Centre established in Zurich. Even in our very first steps, we wanted to contact someone with special expertise in the production and distribution of diagnostic and therapeutic tools. This was certainly important, as we wanted to receive confirmation that our project is indeed considerable and that it could eventually be brought to the public to improve the diagnosis of such a disease. Taking into consideration all the important safety measures against COVID-19, firstly, we scheduled an online meeting to present our project. Through this meeting, he expressed his enthusiasm about our diagnostic tool and he confirmed that the main cause of the high mortality rate of pancreatic cancer and especially Pancreatic Cancer Adenocarcinoma is due to the late diagnosis. So, he validated the value and the impact of our project for the confrontation of PDAC and the fact that it could potentially lead to increased survival rates.
Also, as an oncologist, he emphasized that a diagnostic tool must be specific and sensitive for one disease only and that we should avoid false positive and negative results. After this discussion, we delved into the literature research and we rejected many biomarkers that could not reach the desired specificity. For example, we rejected hsa-miR-21, which we were considering to use initially because it is upregulated in blood both when a patient suffers from first and second-stage pancreatic cancer and pancreatitis. In contrast, we selected two miRs, more specifically hsa-miR-143-3p and hsa-miR-30e-5p, which are not related to the pathophysiology of other diseases or cancer types.
Furthermore, on the 17th of July, we visited the Research Genetic Cancer Centre, where Mr. Apostololu Panagiotis, a colleague of Dr. Papasotiriou Ioannis organized a tour of the company premises to see the workflow of the production of diagnostic devices such as our tool “METIS”. There, our team had the chance to see how an industry, that could potentially sublicence our diagnostic methodology patent, could produce the diagnostic device to sell it to diagnostic centers.
After our tour, we met Dr. Ioannis Papasotiriou. Throughout this meeting, we presented once again our project and our first experimental results, we received feedback on how we can continue the necessary experimental procedures. In this discussion, Dr. Papasotiriou, expressed his interest to license a patent on our project and produce the diagnostic device for PDAC. Moreover, he informed us that he could help our team with the clinical trials, which will follow after the iGEM Competition. This could be achieved since his company cooperates with companies and agencies in Europe that can execute clinical trials through urine samples processing.



| Diagnostic Centers



~Labnet
On the 19th of August we got in touch with Dr. Fani Chatzopoulou, Biologist at LABNET IAE, one of the biggest Diagnostic Centers in Greece. After our project presentation and the analytical description of the diagnostic methodology, which we suggested, we received some comments in this meeting. First, she confirmed that there is a problem with the diagnosis of PDAC as patients are asymptomatic in the first stages of cancer development leading to high mortality. Then, she informed us about the general lab equipment of the microbiological labs globally. Through this description, she pointed out that usually the microbiological labs are not able to store the reagents at -80°C, so we should redefine the storage conditions of our kit and the transfer method. In addition, she emphasized that the diagnostic tool should be cheap in order to be preferred by patients, to benefit the diagnostic center to buy the device and offer our test to the public. Also, she emphasized that the microRNAs are detected in low quantities in the urine samples so before the processing for the final results should recede an amplification method. The most known amplification method is PCR but it requires expensive equipment, reagents, and high temperature. In this way our team decided to use the EXPAR, as an amplification method, that is cheap and can be executed at a low and stable temperature, 37°C. After our decision, we confirmed that simple incubators for this temperature are available to every microbiological lab.




| Regulatory Entities



~European Medicines Agency
The European Medicines Agency (EMA) is the regulatory agency responsible for evaluating, authorizing, and monitoring medicines for human and veterinary use within the European Union (EU) and the European Economic Area (EEA). The agency cooperates closely with national regulatory authorities in EU countries and companies can apply to it to grant a single marketing authorization, which enables them to market the medicine concerned throughout the EU and the EEA. Although our project is in the field of diagnostics and not therapeutics, the communication with an agency that with a single authorization gives access to the market of all European countries could be more than useful to us.
On the 3rd of September, our team and iGEM Patras team had a zoom meeting with Dr. Iordanis Gravanis, Head of Office of the Scientific Advice, Scientific Evidence Generation Department in the EMA. After we presented our projects, we talked about our ideas and the things we should take under consideration when applying for approval. Although he told us that EMA is not responsible for the authorization of diagnostic tools, he informed us about Emergency Use Authorisation. When a diagnostic tool that is referred to a disease with high mortality with no sensitive diagnostic method and no specific therapy, such as pancreatic cancer, is under approval, both EMA and WHO can accelerate the procedure in cooperation with the Notified Bodies involved. Notified Bodies are the national organization authorized by the EU to evaluate diagnostic tools and other products before being placed on the market. He encouraged us to contact the National Organization for Medicines (Greek name: EOF) which is the Notified Bodies of Greece. We listened to his advice and a few days later we had a meeting with a presentative of EOF. All of his advice was valuable to us and we took under consideration the characteristics that our tool should have in order to be a candidate for the Emergency Use Authorisation.





~National Organization for Medicines

National Organization for Medicines (Greek name: EOF) is Greece’s regulatory organization for medicinal products for human and veterinary use, special nutrition foods and nutritional supplements, biocides, medical devices, and cosmetics. Its mission is the protection of Public Health and, in accordance with the European Union’s regulation, all medical devices, and therefore in vitro diagnostic (IVD), too, are evaluated and approved by EOF before they become available to the public as products. Thus, we took the initiative to contact EOF because, for our project to have a big impact on human lives, it should first be available to the general public as a product.
On the 10th of September, our team contacted EOF through zoom and discussed our project “METIS” with the Deputy Head of the Medical Devices Assessment Department, Dr. Virginia Safra. Dr. Safra informed us about in vitro diagnostic current regulation (Regulation 746) to which our kit is subjected to and generally about medical devices regulation (Regulation 745) to which our device is submitted to. Through this presentation, we were given guidelines and advice for the further utilization of our project and the necessary steps for approval by EOF. In addition, we discussed the course of action we should follow through clinical trials and how they must be conducted so that our project can become a product and be put into production. Finally, we received information about the utilization framework of in vitro diagnostics for “Orphan Diseases”. Pancreatic Ductal Adenocarcinoma (PDAC) is a rare type of cancer and due to that approval and clinical trials could be difficult. Dr. Safra informed us about the Emergency Use Listing procedure both by WHO and EOF, for IVD referred to diseases with high mortality and inadequate diagnostic methods. This information definitely affected the final form of our business model and strategy and we really hope that it will make our project easily available to the public.
Last but not least, we couldn't forget to mention our fellow team Patras that participated in this conversation with EOF, too. Although our projects are different in many ways, together we found common ground in the field of diagnostics tools approval and on the common questions we had regarding both our projects. Eventually, we got the best out of our meeting with EOF.






| Entrepreneurship



~Next Stage Challenge Competition
Within the business development of our project we participated in a business competition, the Next Stage Challenge 2021, and in the Finals, which took place on the 16th of September our project won the first prize.
During our participation, coaching sessions were organized with our mentor Mr. Tsoniotis Nikolaos to prepare our Business Model Canva and our pitch deck presentation. In our first session, when presenting our project to the coach, he advised us that it will be very useful if we can develop a general algorithm or software for the simple design of Toehold switches for different biomarkers and miRs that can be used for the diagnosis of other types of cancer. After this comment, the Dry Lab members work on it, firstly to help the future scientists and other teams to develop diagnostic tools for cancer easily and secondly to increase the business value of our project.

For more information visit our Entrepreneurship page:

Entrepreneurship






| Doctors



~Dr. Tsamourlidis Georgios
On the 22nd of April, we got in touch with Doctor Tsamourlidis Georgios, Surgical Resident at the General Hospital of Thessaloniki; "O Agios Demetrios". After describing our diagnostic method, we asked him how can a patient survive after the diagnosis of Pancreatic Ductal Adenocarcinoma and what is the appropriate treatment method. He informed us that after positive diagnostic testing, imaging diagnostic techniques, such as pancreatic specific CT, should follow to determine the location of the tumor. Then, the tumor is removed by surgery, depending on the location of the tumor, as at the early stages, metastasis has not occurred yet. But he emphasized that in order to follow this treatment protocol, doctors should be sure that the patient suffers from pancreatic cancer and not from pancreatitis or another disease. So, he recommended that our diagnostic tool “METIS” must have high sensitivity and specificity for this type of cancer. So our team, to achieve high specificity, added miR-1246 as the third biomarker in the urine since it is upregulated in the urine of patients who suffer from first and second-stage pancreatic cancer. As a result, the combination of these three upregulated molecules will ensure the specificity for the PDAC to continue with the right method of treatment and save the patient’s life.



~Dr. Christos Em. Emmanouilides
On the 20th of September, we had a meeting with Dr. Christos Em. Emmanouilides, a well-known Medical Oncologist in Interbalkan European Medical Center, one of the most well-established private medical centers for cancer therapy in the Balkans. Dr. Emmanouilides, having many years of experience in cancer diagnosis and therapy, gave us valuable advice on the characteristics that our diagnostic tool should have in order to be easily accepted by doctors, hospitals, and centers in the private sector. He emphasized on our method's sensitivity and specificity and how METIS could be adapted to the guidelines for pancreatic cancer diagnosis and everyday clinical practice. In order for METIS to be easily accepted, except for clinical trials, an analysis based on the incidence of PDAC should be conducted to determine whether our method is suitable for screening in the general public as a preventative measure or it should be used as a mean to conclude inconclusive results provided by imaging techniques. In both cases, he noticed the importance of specifying the results of our method using the right calibrators and validating results with an imaging technique, such as a pancreas-specific CT that might be not as sensitive as METIS but it will reduce the risk of false-positive results. Dr. Emmanouilides' advice definitely shaped our project development and our safety form and gave us the extra mile needed to ensure more accurate results using the right calibrators (positive and negative controls) for our analysis.







| POC Diagnostic



During our Human Practices, we met many specialized people that offered their help and shared their experiences and expertise with us. This way they guided us to approach our project from different perspectives. However, the most important adaptation we made to our project was designing a diagnostic device that could facilitate our method and reduce the cost of the test.

This shift was an important outcome of our meetings with professionals from different fields, such as academic research and business. More specifically, we came up with the initial idea after a discussion with Dr. Aivaliotis Michalis, Associate Professor of Biological Chemistry, School of Medicine, AUTH. Another factor necessary for the implementation of such a device is succeeding in quantifying the miRNAs in the sample. We realized the importance of this aspect after a discussion with Leandros Tsiotos, BSc in Biochemistry and Biotechnology, UTH, and iGEM Ambassador. Finally, we decided to put this idea into practice and actually begin the design of the device, after the meeting with Dr. Papasotiriou, as mentioned above. Below, we will analyze how these discussions shaped our project.


~Initial Approach

Concerning the form of the project, our initial approach was to prove that the miRNA sequences, excreted in urine at stages I and II of PDAC, were detectable with the use of toehold switches. Therefore, the structure of our project should be as follows:

Project: miRNA Detection Tool for PDAC
  • 1. Search in the bibliographyalongside bioinformatic analysis for the miRNA sequences
  • 2. Design and analysis of toehold switch sequences for the detection of the miRNA sequences with GFP
  • 3. Confirmation of the detection in the lab


But, after consulting experts on this matter, our project drastically transformed.


~First Configuration

We received positive feedback and constructive criticism about the goal of our project: the detection of the miRNA sequences would provide research material to the scientific community, but it would make no difference in terms of the detection of PDAC and therefore it could not be used short-term.

After a long discussion, we concluded that the detection of miRNAs wasn’t enough; it was crucial for us to find a threshold, a decisive quantity of fluorescence, which would allow the diagnosis of PDAC. Since we wouldn’t conduct clinical studies, this solution should accrue differently: through the correlation of the miRNA quantity to the toehold switches quantity and lastly to the fluorescence quantity, which can be measured using specialized equipment in the lab. Therefore, the structure of the project was shaped as follows:

Project: Diagnostic Tool for PDAC
  • 1. Search in the bibliographyalongside bioinformatic analysis for the miRNA sequences
  • 2. Design and analysis of toehold switch sequences for the detection of the miRNA sequences with GFP
  • 3. Confirmation of the detection in the lab
  • 4. Quantification of fluorescence in the lab
  • 5. Correlation of the data for the finalization of the threshold



~Second Configuration

After multiple sessions, we received sponsorship and constructive criticism about the possible implementation of our project: due to the economical crisis but also the geographical distribution of diagnostic centers across Greece, it is common for the centers to lack specialized equipment and personnel. Our diagnostic tool could only be used in large diagnostic centers and hospitals, being expensive and therefore accessible by a small portion of the population. Considering that these problems are not uniquely met in Greece, but worldwide, our diagnostic tool would remain a long-term solution.

Therefore, we decided to explore the potentials of implementation within at least 2 years by designing a cost-effective portable, plug-and-play fluorometer device. The potential mass production of the device would provide a cheap, easy, fast, and easily accessible diagnostic tool for PDAC. Further study of this idea led us to explore its potentials in entrepreneurship, too. The final structure of the project follows:

Project: a POC diagnostic for PDAC
  • 1. Search in the bibliographyalongside bioinformatic analysis for the miRNA sequences
  • 2. Design and analysis of toehold switch sequences for the detection of the miRNA sequences with GFP
  • 3. Confirmation of the detection in the lab
  • 4. Quantification of fluorescence in the lab
  • 5. Correlation of the data for the finalization of the threshold
  • 6. Design a portable, plug-and-play fluorometer device
  • 7. Create a fully functional diagnostic kit for diagnostic centers





~Workflow

To summarize, this is how our project was shaped after the feedback received by experts:

Project miRNA Detection Tool for PDAC Diagnostic Tool for PDAC POC diagnostic for PDAC
Structure 1. Search in the bibliography and bioinformatic analysis
2. Design and analysis of toehold switch sequences
3. Confirmation
 1. Search in the bibliography and bioinformatic analysis
2. Design and analysis of toehold switch sequences
3. Confirmation
4. Quantification
5. Correlation
 1. Search in the bibliography and bioinformatic analysis
2. Design and analysis of toehold switch sequences
3. Confirmation
4. Quantification
5. Correlation
7. Design a fluorometer device







| Summary



The purpose of our social activities was to validate the importance of our research project for society. We approached entities to cover every aspect of our diagnostic tool development and distribution.


Academic community ~Dr. Lefkothea Papadopoulou
Industries ~R.G.C.C.
Diagnostic Centers ~Labnet
Regulatory Entities ~European Medicines Agency
~National Organization for Medicines
Entrepreneurship ~Next Stage Challenge Competition
Doctors ~Dr. Tsamourlidis Georgios
~Dr. Christos Em. Emmanouilides